Paul S. Mishkin
Lawyers
Filters
Syngenta agricultural products antitrust lawsuits
We represent Syngenta in cases involving “crop inputs” and “loyalty rebate programs”
Class certification denial in NatWest FX litigation
We achieved the denial of class certification in a claim involving retail foreign exchange investors
NatWest dismissal from financial product litigations
We secured NatWest's dismissal from numerous antitrust litigations alleging collusion in financial markets
BBVA antitrust litigation dismissal
The court dismissed all claims involving alleged manipulation of Mexican government bond prices
Liaison counsel for all bank defendants in LIBOR litigation
We successfully obtained dismissals of multiple claims
NYSE secures SEC approval of direct listing rule changes
Davis Polk successfully represented the New York Stock Exchange LLC (“NYSE”) before the Securities and Exchange Commission (the “SEC” or “Commission”) in connection with NYSE’s proposed…
NYSE asks SEC to lift stay of NYSE’s direct listing rule changes
On September 4, 2020, Davis Polk filed a motion with the Securities and Exchange Commission (the “SEC” or “Commission”) on behalf of the New York Stock Exchange LLC (“NYSE”) to lift an…
Complete victory for AstraZeneca in Anti-Terrorism Act case
On July 17, 2020, Davis Polk secured a complete dismissal on behalf of its client, AstraZeneca, in an Anti-Terrorism Act (“ATA”) lawsuit asserted against several pharmaceutical and medical…
D.C. Circuit victory for NYSE
Davis Polk achieved a significant victory this week for its client, the New York Stock Exchange (“NYSE”), in a dispute between the three largest U.S. stock-exchange groups and the…
Davis Polk Obtains Stay of Transaction Fee Pilot Rule for NYSE
Davis Polk secured a victory for the New York Stock Exchange (“NYSE”) in an ongoing highly publicized dispute between the three largest U.S. stock-exchange groups and the…